Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Adeno-associated virus vector containing an adenine base editor provides an effective strategy to treat hereditary hearing loss caused by the R75W mutation. Moreover, this gene editing technology can ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
NanoMosaic published a scientific white paper detailing a study conducted with Bristol Myers Squibb (BMS) that explores the potential of nanoneedle technology as a tool for advancing the understanding ...
Hosted on MSN
Q&A: How organoids could make gene therapy trials safer by identifying hidden risks early on
Ryuji Morizane, MD, Ph.D., of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, ...
SPRING HOUSE, Pa. and WATERTOWN, Mass., March 17, 2025 /PRNewswire/ -- ChromaTan Inc., and Landmark Bio PBLLC, today announced they have been awarded a grant from the National Institute for Innovation ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results